Aspirin and cancer prevention

 
aspirin Nearly 900 patients took part in the trial

Related Stories

It's 11 months since I began taking a daily low-dose - 75mg - of aspirin in the hope that it might reduce my long term risk of developing cancer.

This personal decision came after a study in the Lancet suggested that aspirin use could substantially cut the risk of cancer.

New research from Newcastle University seems to support the theory that aspirin may have a preventive effect.

Also published in the Lancet, it shows that, over two years, taking aspirin reduced the incidence of bowel cancer by 63% in a group of 861 people who were at high risk of the disease because they had Lynch syndrome.

Last year's study had been designed to look at preventing heart disease, but it also found that long-term use of aspirin reduced deaths from cancer by around 25%.

Questions

This latest study took things forward as it was the first aspirin trial where bowel cancer incidence was the focus.

But there are still questions outstanding. The specific group of patients involved were already at high risk of developing bowel cancer. But although this group benefited, what level of protection might be gained by other adults?

The researchers are also unclear exactly how aspirin works and what amount is needed.

Those on the trial took 600mg aspirin daily which is a much bigger dose than the 75 mg that many middle-aged people like me take to reduce their risk of cardiovascular disease.

Then there is the risk of side-effects including bleeding from the stomach and gut.

I wrote last year: "If I get an intestinal bleed in a few months time and am taken to hospital needing a blood transfusion, then it will be easy to argue that I got it wrong."

Well, so far so good.

US experts said these latest findings might "tip the scales" towards more people choosing to take aspirin in a bid to prevent cancer.

But the decision must still rest with individuals who need to look at the potential risks, as well as the benefits.

 
Fergus Walsh Article written by Fergus Walsh Fergus Walsh Medical correspondent

Superbugs to kill 'more than cancer' by 2050

Drug resistant infections will kill an extra 10 million people a year worldwide by 2050 unless action is taken, a study says.

Read full article

More on This Story

Related Stories

The BBC is not responsible for the content of external Internet sites

Comments

This entry is now closed for comments

Jump to comments pagination
 
  • rate this
    0

    Comment number 4.

    Canadian Cancer Society is funding new study to help sort various intake measures measured against cancer prevention. Dr Anita Koushik's Team will work with group of women, some with ovarian cancer & some without, about lifestyle choices which may influence cancer development, particularly vitamin D, a possible cancer inhibitor, & use of compounds that regulate inflammation, such as ASPIRIN.

  • rate this
    0

    Comment number 3.

    I would exercise caution. My father recovered from bowel cancer 8 years ago, and was later prescribed daily aspirin to control angina. He died 6 weeks ago, aged 76 years, from advanced and metastised oesophageal/stomach cancer, only diagnosed at the end of May

  • rate this
    0

    Comment number 2.

    I'm a healthy 55. Since the Peter Rothwell trials in The Lancet in late 2010 I've been taking, like Fergus Walsh, 75mg/day aspirin to reduce risk of cancer.

  • rate this
    0

    Comment number 1.

    another encouraging word... except -- the downside found elsewhere that aspirin causes___fill in the blank. I recommend 5000MG of vitamin C daily.

 
 

Features & Analysis

BBC Future

(Thinkstock)

Why do we fart more on planes?

And can airlines ease our discomfort? Read more...

Programmes

  • (File photo) A man dressed as Father Christmas with a sleigh and a reindeer Click Watch

    A website which tracks Father Christmas, plus other sites and apps to keep you entertained

BBC © 2014 The BBC is not responsible for the content of external sites. Read more.

This page is best viewed in an up-to-date web browser with style sheets (CSS) enabled. While you will be able to view the content of this page in your current browser, you will not be able to get the full visual experience. Please consider upgrading your browser software or enabling style sheets (CSS) if you are able to do so.